Innoviva Market Cap 2010-2024 | INVA

Innoviva market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Innoviva market cap as of January 20, 2025 is $1.16B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.163B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $688.937B 71.36
Johnson & Johnson (JNJ) United States $353.993B 14.36
Novo Nordisk (NVO) Denmark $353.124B 25.47
AbbVie (ABBV) United States $303.171B 15.96
Merck (MRK) United States $247.702B 16.46
Roche Holding AG (RHHBY) Switzerland $231.838B 0.00
AstraZeneca (AZN) United Kingdom $206.533B 17.57
Novartis AG (NVS) Switzerland $199.351B 13.25
Pfizer (PFE) United States $149.042B 10.19
Sanofi (SNY) $128.770B 11.66
Bayer (BAYRY) Germany $21.338B 3.42